Cargando…

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions

Nafamostat mesylate is a serine protease inhibitor used in the treatment of acute pancreatitis. The impurities in nafamostat mesylate, the active pharmaceutical ingredient (API), were profiled via high performance liquid chromatography tandem ion trap coupled with time-of-flight mass spectrometer (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuxin, An, Lufan, Zhang, Lin, Wang, Rulin, Tian, Yuan, Zhang, Zunjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474109/
https://www.ncbi.nlm.nih.gov/pubmed/32923008
http://dx.doi.org/10.1016/j.jpha.2020.03.002
Descripción
Sumario:Nafamostat mesylate is a serine protease inhibitor used in the treatment of acute pancreatitis. The impurities in nafamostat mesylate, the active pharmaceutical ingredient (API), were profiled via high performance liquid chromatography tandem ion trap coupled with time-of-flight mass spectrometer (HPLC-IT-TOF/MS). The chromatography was performed on an ACE-3 C(18) column (200 mm × 4.6 mm, 3 μm) using methanol and 0.1% formic acid in purified water as mobile phase at a flow rate of 1.0 mL/min. The ions were detected by IT-TOF/MS with a full-scan mass analysis from m/z 100 to 800. In total, eleven impurities were detected in nafamostat mesylate API. The impurity profile was estimated based on the HPLC-IT-TOF/MS data, including accurate masses, MS(n) fingerprints of fragmentation pathways and a series of double-charged ions. Finally, seven impurities were identified and reported for the first time. The results will provide technical support for the quality control and clinical safety of nafamostat mesylate.